Prescription Drugs: Making Generic Biological Medicines Easier to Get
The Senate must act next: a Senate floor vote.
No action since July 2026
The bill has strong bipartisan support and has successfully moved out of a key Senate committee, but it still faces the challenge of passing the full Senate and the House.
This bill’s path across every version that has carried it.
Scores run from -100 (strongly harmful) to +100 (strongly beneficial) for each group, combining impact, certainty, scope, and duration ratings of 1-5. How impact scoring works
Smaller biosimilar developers currently must run costly clinical switching studies to earn an interchangeable label, which can cost tens of millions of dollars. Removing that requirement lowers the barrier for smaller manufacturers to bring biosimilars to market and compete with large brand-name biologic makers.
“the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product is biosimilar to the reference product”
Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
The bill is now on the schedule for the full chamber to consider. It's in line for debate and a vote.
Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
The committee approved this bill and is sending it to the full chamber for a vote. This is a significant step — most bills never get this far.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
The Association for Accessible Medicines lauded the Senate HELP Committee for passing the Biosimilar Red Tape Elimination Act. The bill would eliminate separate statutory requirements for interchangeability, which AAM argues create unnecessary costs and discourage market competition.
Lawmakers are advancing the Biosimilar Red Tape Elimination Act across both chambers. The legislation would deem FDA-licensed biosimilars interchangeable with reference products, removing the unique U.S. requirement for switching studies that often delays lower-cost alternatives.
Fierce Pharma reports on the push to remove bureaucratic barriers to biosimilar access. The Biosimilar Red Tape Elimination Act specifically revises the statutory definition of interchangeability, effectively removing the distinction between standard biosimilars and interchangeable ones.
No votes recorded for this bill yet.
Document Type
Congressional Bill
Official Title
Biosimilar Red Tape Elimination Act
Analysis generated by AI. Always verify with official sources.